Stroke prevention in NVAF

__________

Xarelto is indicated for stroke prevention in adults with non-valvular atrial fibrillation with one or more risk factors

Treatment of PE/DVT and prevention of recurrent VTE

__________

Xarelto is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DTV and PE in adults

Xarelto is indicated for the treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation

Prevention of Atherothrombotic Events in Peripheral Artery Disease

__________

Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adults with symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

Prevention of Atherothrombotic Events in Coronary Artery Disease

__________

Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adults with coronary artery disease (CAD) at high risk of ischaemic events

Secondary prevention in ACS

__________

Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after acute coronary syndrome with elevated cardiac biomarkers

Prevention of VTE after elective hip replacement surgery

__________

The first approved indication for Xarelto was for the prevention of venous thromboembolism in adults undergoing elective hip replacement surgery

Prevention of VTE after elective knee replacement surgery

__________

The first approved indication for Xarelto was for the prevention of venous thromboembolism in adults undergoing elective knee replacement surgery